Table 1 Baseline characteristics of the total cohort and in patients with and without metastasis at diagnosis or during follow-up
Total sample (N = 524) | Non metastatic (N = 302) | Metastatic (N = 222) | p-value | |
|---|---|---|---|---|
Follow-up time (median, IQR) (months) | 50 (32-72) | |||
Age (mean, SD) | 61.6 (16.6) | 60.1 (17.3) | 63.7 (15.5) | 0.032 |
Sex (n, %) | 0.582 | |||
Male | 283 (54) | 160 (53) | 123 (55.4) | |
Female | 241 (46) | 142 (47) | 99 (44.6) | |
Anatomic location (n, %) | 0.009 | |||
Head and neck | 84 (15.9) | 47 (15.6) | 37 (16.7) | |
Trunk | 182 (34.8) | 109 (36.1) | 73 (32.9) | |
UE | 72 (13.7) | 44 (14.6) | 28 (12.6) | |
LE | 110 (21) | 72 (23.8) | 38 (17.1) | |
Acral | 72 (13.8) | 27 (8.9) | 45 (20.3) | |
Subungual | 4 (0.8) | 3 (1) | 1 (0.4) | |
Breslow thickness (mean, SD) | 3.08 (3.36) | 1.96 (1.74) | 4.59 (4.32) | <0.001 |
Histopathologic ulceration (Present) (n, %) | 174 (33.2) | 56 (18.5) | 118 (53.2) | <0.001 |
Mitosis (n = 444) (n, %) | <0.001 | |||
Absent | 72 (16.2) | 63 (25.4) | 9 (4.6) | |
1-5/mm2 | 221 (49.8) | 138 (55.6) | 83 (42.3) | |
>5/mm2 | 151 (34) | 47 (19) | 104 (53.1) | |
SLNB (n, %) | <0.001 | |||
Not performed | 177 (33.9) | 119 (39.6) | 58 (26.1) | |
Negative | 234 (44.8) | 181 (60.4) | 53 (23.9) | |
Positive | 111 (21.3) | - | 111 (50) | |
CLND (n, %) | <0.001 | |||
Not performed | 411 (78.7) | 299 (99.7) | 112 (50.5) | |
Negative | 58 (11.1) | 1 (0.3) | 57 (25.7) | |
Positive | 53 (10.2) | - | 53 (23.9) | |
AJCC stage (8th edition) | Stage at diagnosis (n, %) | Stage at last f.u (n, %) | ||
IB | 227 (43.3) | 204 (38.9) | ||
IIA | 66 (12.6) | 52 (9.9) | ||
IIB | 53 (10.1) | 31 (5.9) | ||
IIC | 35 (6.7) | 15 (2.9) | ||
III | 95 (18.1) | 67 (12.8) | ||
IV | 48 (9.2) | 155 (29.6) | ||
